Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.5441
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 139746394600.0
- FreeCF/Share 1.9771
- PFCF 12.4551
- PE 17.7335
- Debt/Assets 0.2946
- DivYield 0.0862
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
3 Ultra-Safe Dividend Stocks That Yield Over 5%
Published: July 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points These dividend stocks yield 5% or more.
Read More
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Published: July 17, 2025 by: CNBC
Sentiment: Neutral
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
Read More
Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Harvesting Portfolio is thriving, generating strong recurring income and capital appreciation, with forward dividend income nearing $2,400 and a yield over 8%. My disciplined weekly allocation and diversified approach—spanning 102 positions—have mitigated downside risk and steadily grown income, even during market uncertainty. Recent additions to Bristol Myers Squibb, BP, and BSTZ reflect my focus on undervalued, high-yield opportunities positioned for growth amid potential Fed rate cuts.
Read More
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
Published: July 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
Read More
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Published: July 17, 2025 by: Reuters
Sentiment: Positive
US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.
Read More
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
Published: July 17, 2025 by: WSJ
Sentiment: Positive
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Read More
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
Read More
“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
Published: July 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who want to keep their money are in bonds.
Read More
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Will The Tariff “Taco Trade” End The Rally? 5 High-Yield Value Stocks Are Strong Buys Now
Published: July 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Value stocks are generally companies that trade at a price lower than their fundamental value or what their performance suggests they should be worth.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Published: July 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
Read More
2 Stocks to Buy With Less Than $50
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
Read More
Pfizer: Options Activity Speaks Bullish
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Positive
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and innovation, with recent pipeline successes as catalysts. Despite macro risks and ROIC below historical averages, PFE stock's 52% upside to fair value and compelling yield make it a rare value opportunity.
Read More
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Read More
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
Read More
Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North America leading. New launches by companies like OSRAM enhance growth. The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North …
Read More
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Read More
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
Read More
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding its cost-savings program to a massive $7.7 billion by 2027, aiming to create a powerful EPS growth story despite flat revenues. Pfizer's non-COVID portfolio is firing on all cylinders, with key drugs like Nurtec and Padcev showing robust double-digit growth, proving underlying business health.
Read More
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced Dividend Dogs of the GASV are currently fair-priced and ready to buy for income investors. Top ten GASV stocks offer projected average net gains of 32.99% by June 2026, with yields ranging from 8.94% to 13.81%.
Read More
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
Published: June 25, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. In.
Read More
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Read More
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.
Read More
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Read More
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000